MX2009008620A - Un metodo para mejorar la respuesta de celulas t. - Google Patents
Un metodo para mejorar la respuesta de celulas t.Info
- Publication number
- MX2009008620A MX2009008620A MX2009008620A MX2009008620A MX2009008620A MX 2009008620 A MX2009008620 A MX 2009008620A MX 2009008620 A MX2009008620 A MX 2009008620A MX 2009008620 A MX2009008620 A MX 2009008620A MX 2009008620 A MX2009008620 A MX 2009008620A
- Authority
- MX
- Mexico
- Prior art keywords
- enhancing
- antigen
- invention disclosed
- immunogenic composition
- cell response
- Prior art date
Links
- 230000005867 T cell response Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 230000007503 antigenic stimulation Effects 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
- 230000008512 biological response Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000000091 immunopotentiator Effects 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las modalidades de la invención descrita en la presente se refieren a métodos y composiciones para incrementar de manera exponencial la estimulación antigénica de las respuestas de células T, MHC CD8+ clase I sobre las basadas en la técnica. Algunas modalidades se refieren a una composición inmunogénica que mejora una respuesta inmune en un sujeto. En algunas modalidades, la composición inmunogénica comprende un antígeno en combinación con un inmunopotenciador o un modificador de la respuesta biológica (BRM). En general, la invención descrita en la presente demuestra que incrementar la estimulación antigénica en una manera independiente de la dosis del antígeno mejora la ininunogenicidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90198007P | 2007-02-15 | 2007-02-15 | |
PCT/US2008/002044 WO2008100598A2 (en) | 2007-02-15 | 2008-02-15 | A method for enhancing t cell response |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009008620A true MX2009008620A (es) | 2009-10-22 |
Family
ID=39690701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009008620A MX2009008620A (es) | 2007-02-15 | 2008-02-15 | Un metodo para mejorar la respuesta de celulas t. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080199485A1 (es) |
EP (2) | EP2481418A1 (es) |
JP (2) | JP5755839B2 (es) |
CN (2) | CN103736086A (es) |
AU (1) | AU2008216669B2 (es) |
CA (1) | CA2678353A1 (es) |
ES (1) | ES2527412T3 (es) |
HK (2) | HK1139595A1 (es) |
MX (1) | MX2009008620A (es) |
WO (1) | WO2008100598A2 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
CN101198620A (zh) | 2005-06-17 | 2008-06-11 | 曼康公司 | 激发针对在癌细胞和肿瘤基质上表达的结构域和亚结构域表位的多价免疫应答的方法和组合物 |
CA2682580A1 (en) | 2007-03-30 | 2008-10-09 | Duke University | A method of modulating the activity of a nucleic acid molecule |
US8728465B2 (en) * | 2008-06-17 | 2014-05-20 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
DE102008061522A1 (de) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
US20110257458A1 (en) * | 2008-12-24 | 2011-10-20 | Cedars-Sinai Medical Center | Method of using tumor cell debris to reduce brain tumor recurrence or growth |
IN2012DN02345A (es) | 2009-09-16 | 2015-08-21 | Univ Duke | |
CA2778707A1 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
ES2769326T3 (es) | 2010-02-05 | 2020-06-25 | Univ Cornell | Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor |
BR112015013557B1 (pt) | 2012-12-11 | 2021-12-14 | Albert Einstein College Of Medicine | Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante |
US20150037374A1 (en) * | 2013-07-31 | 2015-02-05 | Csl Limited | Anti-tumor compositions and uses thereof |
WO2015161094A1 (en) | 2014-04-16 | 2015-10-22 | Duke University | Electrospun cationic nanofibers and methods of making and using the same |
BR112017018954A2 (pt) | 2015-03-06 | 2018-05-15 | Beyondspring Pharmaceuticals, Inc. | uso de forma mutante de proteína ras e método para tratar câncer |
WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
CA2984643A1 (en) | 2015-05-13 | 2016-11-17 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
CN113735834B (zh) | 2015-07-13 | 2023-06-13 | 大连万春布林医药有限公司 | 普那布林组合物 |
IL260933B2 (en) * | 2016-02-08 | 2023-04-01 | Beyondspring Pharmaceuticals Inc | Preparations containing tocorsol or its analogues |
KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
KR20190015361A (ko) | 2016-06-06 | 2019-02-13 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
DK3558339T3 (da) | 2016-12-22 | 2024-02-26 | Cue Biopharma Inc | T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf |
US11733235B2 (en) | 2016-12-27 | 2023-08-22 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating immunogenicity of test substance |
WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
SG11201907023UA (en) | 2017-02-01 | 2019-08-27 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
CA3096909A1 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
CN111135310B (zh) * | 2019-12-24 | 2021-05-07 | 江苏省人民医院(南京医科大学第一附属医院) | 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用 |
CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
CN116262779A (zh) * | 2021-12-14 | 2023-06-16 | 深圳先进技术研究院 | 一种单细胞筛选鉴定人***瘤病毒特异性tcr的方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778879A (en) * | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
DE4143467C2 (de) | 1991-05-17 | 1995-02-09 | Max Planck Gesellschaft | Peptidmotiv und dessen Verwendung |
US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
DE4423392A1 (de) | 1994-07-04 | 1996-01-11 | Birsner & Grob Biotech Gmbh | Verfahren zur Identifizierung antigener Peptide |
WO1996027008A2 (de) | 1995-02-28 | 1996-09-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin | Mittel zur therapie von tumoren und anderen hyperplasien |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
WO1997047271A2 (en) * | 1996-06-12 | 1997-12-18 | Yajun Guo | Cellular vaccines and immunotherapeutics and methods for their preparation |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
PT1003548E (pt) | 1997-07-10 | 2006-09-29 | Mannkind Corp | Dispositivo para a inducao de uma resposta por ctl |
US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
ATE408690T1 (de) * | 1998-03-16 | 2008-10-15 | Alk Abello As | Mutiertes rekombinantes allergen |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US20020165176A1 (en) * | 2000-05-01 | 2002-11-07 | Haynes Joel R. | Nucleic acid immunization |
GB0023008D0 (en) * | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
WO2002069907A2 (en) * | 2001-03-07 | 2002-09-12 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
WO2003063770A2 (en) | 2001-11-07 | 2003-08-07 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
NZ519363A (en) * | 2002-06-05 | 2004-02-27 | Agres Ltd | A novel drug dosing regimen |
CN1691964A (zh) | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
AU2004253479B9 (en) * | 2003-06-17 | 2011-10-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
ATE546153T1 (de) | 2003-06-17 | 2012-03-15 | Mannkind Corp | Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen |
US6997074B2 (en) | 2003-10-30 | 2006-02-14 | Eaton Corporation | Prediction of destination gear for progressive shift feature |
KR20100092031A (ko) * | 2004-06-17 | 2010-08-19 | 맨카인드 코포레이션 | 에피토프 유사체 |
CA2570998A1 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Improved efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
CA2592972A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
JP2008526760A (ja) | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用 |
AU2005321940B2 (en) * | 2004-12-29 | 2012-04-19 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
CN101146550B (zh) * | 2004-12-29 | 2013-04-17 | 曼康公司 | 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途 |
WO2006120474A2 (en) * | 2005-05-13 | 2006-11-16 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against tumor antigens |
-
2008
- 2008-02-15 US US12/070,156 patent/US20080199485A1/en not_active Abandoned
- 2008-02-15 AU AU2008216669A patent/AU2008216669B2/en not_active Ceased
- 2008-02-15 CN CN201410026166.0A patent/CN103736086A/zh active Pending
- 2008-02-15 CN CN200880012207.3A patent/CN101657213B/zh not_active Expired - Fee Related
- 2008-02-15 JP JP2009549627A patent/JP5755839B2/ja not_active Expired - Fee Related
- 2008-02-15 EP EP12165994A patent/EP2481418A1/en not_active Withdrawn
- 2008-02-15 WO PCT/US2008/002044 patent/WO2008100598A2/en active Application Filing
- 2008-02-15 MX MX2009008620A patent/MX2009008620A/es active IP Right Grant
- 2008-02-15 ES ES08725654.1T patent/ES2527412T3/es active Active
- 2008-02-15 EP EP08725654.1A patent/EP2129389B1/en not_active Not-in-force
- 2008-02-15 CA CA002678353A patent/CA2678353A1/en not_active Abandoned
-
2010
- 2010-06-09 HK HK10105740.0A patent/HK1139595A1/xx not_active IP Right Cessation
- 2010-08-17 HK HK10107835.2A patent/HK1141251A1/xx not_active IP Right Cessation
-
2013
- 2013-11-25 JP JP2013242826A patent/JP2014043459A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2014043459A (ja) | 2014-03-13 |
AU2008216669A1 (en) | 2008-08-21 |
EP2129389A2 (en) | 2009-12-09 |
AU2008216669B2 (en) | 2013-12-12 |
CN103736086A (zh) | 2014-04-23 |
CN101657213A (zh) | 2010-02-24 |
US20080199485A1 (en) | 2008-08-21 |
JP2010519205A (ja) | 2010-06-03 |
CN101657213B (zh) | 2014-02-26 |
WO2008100598A2 (en) | 2008-08-21 |
HK1139595A1 (en) | 2010-09-24 |
EP2481418A1 (en) | 2012-08-01 |
WO2008100598A3 (en) | 2008-12-31 |
HK1141251A1 (en) | 2010-11-05 |
EP2129389B1 (en) | 2014-10-08 |
ES2527412T3 (es) | 2015-01-23 |
CA2678353A1 (en) | 2008-08-21 |
JP5755839B2 (ja) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008620A (es) | Un metodo para mejorar la respuesta de celulas t. | |
MXPA05013973A (es) | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. | |
WO2008039874A3 (en) | Cancer stem cell antigen vaccines and methods | |
MY172421A (en) | Immunostimulatory oligonucleotides | |
FR2919804B1 (fr) | Composition et vaccin therapeutique anti-tumoral | |
SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
MX363307B (es) | Plataformas para suministro de antigenos. | |
PH12014501836A1 (en) | Novel adjuvant compositions | |
IN2014DN08830A (es) | ||
MX2010001054A (es) | Composiciones adyuvantes antigenicas y metodos. | |
AU2016204319A1 (en) | Methods and compositions for producing squalene using yeast | |
IN2012DN01898A (es) | ||
SG162817A1 (en) | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
TR201802380T4 (tr) | Benzonaftiridin içeren aşılar. | |
MX2013001527A (es) | Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos. | |
MY143347A (en) | Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
WO2006071983A3 (en) | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines | |
WO2011109833A3 (en) | Induced dendritic cell compositions and uses thereof | |
BRPI0520330A2 (pt) | adjuvante a base de ácido polinosìnico-policitidìlico | |
GB0503936D0 (en) | Method | |
WO2007130555A3 (en) | Augmentation of immune response to cancer vaccine | |
WO2008127296A3 (en) | Methods and compositions for treating tularemia | |
WO2010045573A3 (en) | Tumor vaccine | |
WO2009101475A3 (en) | Use of glycosylceramides for enhancing the immune response to antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |